


Concise Asymmetric Synthesis of Kweichowenol A

David B. Konrad^a Bilal Kicin^aDirk Trauner^{*a,b} ^a Department of Chemistry, Ludwig-Maximilians University Munich, Butenandtstraße 5-13, 81377 München, Germany^b Department of Chemistry, New York University, 100 Washington Square East, Room 712, New York, 10003, USA
dirktrauner@nyu.eduDedicated to E.J. Corey on the Occasion of his 90th Birthday
Published as part of the 30 Years SYNLETT – Pearl Anniversary Issue

Received: 22.08.2018

Accepted after revision: 24.10.2018

Published online: 17.12.2018

DOI: 10.1055/s-0037-1610390; Art ID: st-2018-b0541-I


License terms: 

Abstract An asymmetric 11-step synthesis of the polyoxygenated cyclohexene natural product kweichowenol A from the traditional Chinese medicinal herb *Uvaria kweichowensis* is reported. The oxygenation pattern was installed on a linear precursor by exploiting the acyclic stereocontrol of the Kiyooka aldol reaction, as well as Cram chelate-controlled Grignard reactions. Ring-closing metathesis and a selective benzylation then gave the natural product.

Key words kweichowenol A, Kiyooka aldol, asymmetric synthesis, natural product synthesis, acyclic stereocontrol

The flowering plants of the *Uvaria* genus are widely distributed in southern and southwestern China as well as southeastern Asian countries.¹ Prominent members of this genus are commonly used in traditional Chinese medicine as herbs to treat inflammation and tumors.² For example, the roots and leaves of *Uvaria micropara* are used to prepare the herb Zi Yu Pan, whereas *Uvaria grandiflora* is used for the preparation of the herb Shan Jiao Zi.³ This has attracted much attention to their secondary metabolites and it was found that they contain a wealth of polyoxygenated cyclohexenes.^{4–8} Kweichowenol A (**1**), C (**2**), and D (**3**, Scheme 1), for instance, were extracted from *Uvaria kweichowensis*. They incorporate distinct benzoyl esters at their C3- and C6-positions but differ in their C1- and C7-substitution.^{7–9} Kweichowenol A (**1**) and C (**2**) contain unusual acetone- and acetaldehyde-derived spiro 1,3-dioxolane moieties^{10–14} whereas kweichowenol D contains a 1,2-diol. These cyclohexenes share the oxygenation pattern with the kweichowenol-type natural products ferrudiol (**4**) and ellipsepiopsol B (**5**) which were isolated from *Uvaria ferruginea* and the closely related *Ellipsepiopsis cherrevensis*, respective-

ly.^{6,9,15} Ferrudiol (**4**) and ellipsepiopsol B (**5**) have shown to inhibit efflux-related antibiotic resistance in *Staphylococcus aureus* whereas kweichowenol A, C, and D showed antitumor activities against the bronchogenic carcinoma cells A549, SK-MES-1, and NCI-H446.^{7,8,16}




We were intrigued by the oxygenation pattern of the kweichowenols, since it is also present in more complex targets such as the members of the tetrodotoxin family of natural products.^{17,18} This prompted us to develop a synthetic approach to the kweichowenols, which is outlined in Scheme 1. Our retrosynthesis focused on kweichowenol A (**1**), which could serve as a precursor to kweichowenol C (**2**), D (**3**), ferrudiol (**4**), and ellipsepiopsol B (**5**). To enable a rapid, stereoselective construction of the fully functionalized cyclohexene core, we planned to exploit acyclic stereo-

control and cyclize the resulting linear precursor **6** using a ring-closing metathesis (RCM). On this linear precursor **6**, the C3 and C6 stereocenters could be diastereoselectively installed using Grignard additions into the corresponding aldehydes via Cram chelate transition states.¹⁹ These disconnections led to the aldehyde **7** which could be accessed through a Kiyooka aldol reaction.²⁰

Our synthesis of kweichowenol A (**1**) starts with the preparation of the TBS ketene acetal **9** from acetonide ester **8** (Scheme 2). The acetonide ester **8** could be commercially obtained or synthesized on decagram scale using a 3-step sequence that started from serine and required only one purification step (see Supporting Information).


The Kiyooka aldol reaction is known to proceed with excellent enantioselectivity and diastereoselectivity if disubstituted *tert*-butyldimethylsilyl (TBS) ketene acetals are used as nucleophiles.²¹ The use of **9** as a nucleophile in Kiyooka aldol reactions was pioneered by Kalesse who prepared ent-**7** on a small scale.²⁰ For the synthesis of kweichowenol A, we devised a modified procedure for the multigram scale synthesis of aldehyde **7**. Our procedure relied on a *D*-valine-derived oxazaborolidinone reagent **10** which initiated the asymmetric addition of TBS ketene acetal **9** to cinnamaldehyde (**11**). In contrast to the TMS ketene acetal nucleophiles in Mukaiyama aldol reactions, the use of a TBS-ketene acetal enables the *in situ* reduction of the latent ester group of **9** to the corresponding mixed *tert*-butyldi-

methylsilanol methanol acetal via a hydride transfer from the oxazaborolidinone **10** to the reaction intermediate. This powerful opening step installed the contiguous C1 and C2 stereocenters (**12**) in a single transformation.²² To liberate the aldehyde functionality **7**, the TBS group could be transferred from the acetal moiety (**12**) to the C2 alcohol with NaHMDS. By subjecting aldehyde **7** to NMR analysis, we found that the C1 tertiary alcohol and the C2 secondary alcohol stereocenters were formed with 5.4:1.0 dr. Thereafter, we determined that the major diastereomer of **7** was formed with 85% ee by using Mosher ester analysis (see Supporting Information). The secondary alcohol at C6 was installed through a diastereoselective addition of ethynylmagnesium chloride to aldehyde **7**, which presumably proceeded via a 5-membered Cram chelate transition state.¹⁹ By directly intercepting the magnesium alkoxylate intermediate with benzoyl chloride, alkyne **13** was obtained in a one-pot sequence with 60% yield. A successful Upjohn dihydroxylation required the use of citric acid as an additive and was followed by a Lindlar hydrogenation to generate a vinyl group (**14**). Sodium periodate mediated Criegee oxidation afforded aldehyde **15**. The C3 stereocenter was introduced by a second Cram chelate-controlled addition, in this case of vinylmagnesium chloride, which provided vinyl alcohol **6** in good yield. We subjected the resultant diene **6** to a RCM, using the second-generation Hoveyda–Grubbs catalyst (HG-II), and obtained the fully oxygenated cyclohexene **16**. It is



Scheme 2 Asymmetric synthesis of kweichowenol A. *Reagents and conditions:* 1) TBSCl, LiHMDS, THF/HMPA, $-78\text{ }^{\circ}\text{C} \rightarrow 0\text{ }^{\circ}\text{C}$, then **8**, $-78\text{ }^{\circ}\text{C}$; 2) *N*-Ts-*D*-valine, $\text{BH}_3\text{-THF}$, CH_2Cl_2 , $0\text{ }^{\circ}\text{C} \rightarrow \text{rt}$, then **11**, **9**, $-78\text{ }^{\circ}\text{C}$; 3) NaHMDS, THF, $-78\text{ }^{\circ}\text{C} \rightarrow 0\text{ }^{\circ}\text{C}$; 4) ethynylmagnesium chloride, THF, $-78\text{ }^{\circ}\text{C} \rightarrow 0\text{ }^{\circ}\text{C}$, then BzCl, DMAP, $0\text{ }^{\circ}\text{C} \rightarrow \text{rt}$; 5) OsO_4 , NMO, citric acid, *t*-BuOH/acetone/ H_2O , $60\text{ }^{\circ}\text{C}$; 6) Lindlar cat., H_2 , EtOAc/pyridine; 7) NaIO_4 , THF/ H_2O ; 8) vinylmagnesium chloride, THF, $-78\text{ }^{\circ}\text{C} \rightarrow 0\text{ }^{\circ}\text{C}$; 9) HG-II, PhMe, $50\text{ }^{\circ}\text{C}$; 10) TASF, DMF; 11) BzCl, pyridine, $-27\text{ }^{\circ}\text{C} \rightarrow -20\text{ }^{\circ}\text{C}$. DMAP = 4-(dimethylamino)pyridine, HG-II = second-generation Hoveyda–Grubbs catalyst, HMDS = bis(trimethylsilyl)amide, HMPA = hexamethylphosphoramide, NMO = *N*-methylmorpholine *N*-oxide, TASF = tris(dimethylamino)sulfonium difluorotrimethylsilicate, TBS = *tert*-butyldimethylsilyl.

worth noting, that the free allylic C3 alcohol was essential for a successful RCM reaction and a successful TBS deprotection with tris(dimethylamino)sulfonium difluorotrimethylsilicate (TASF). The resulting diol **17** was regioselectively benzoylated at the sterically more accessible C3 alcohol by using benzoyl chloride in pyridine at low temperatures. These optimized conditions provided kweichowenol A (**1**) in good yield.²³ To confirm the structure of the natural product and gain insight into its preferred conformation, we subjected a sample of **1** to X-ray analysis (Scheme 3). Remarkably, kweichowenol A (**1**) crystallized as a racemate from the enantioenriched mixture that was obtained through the synthesis.



In summary, we have devised a short asymmetric synthesis of the polyoxygenated cyclohexene natural product kweichowenol A (**1**), which proceeds in 11 steps starting from commercially available starting materials. The installation of the oxygenation pattern on a linear precursor allowed a rapid access to the cyclohexene core by exploiting acyclic stereocontrol. Carbon-carbon bonds were formed using a Kiyooka aldol reaction, Cram chelate-controlled Grignard reactions, and a RCM. Due to the common cyclohexene oxygenation pattern, kweichowenol A (**1**) could serve as a precursor to other members of the kweichowenol-type natural product family, such as kweichowenol C (**2**), kweichowenol D (**3**), ferrudiol (**4**), and ellipseiopsol B (**5**). It is also worth noting that the C1, C2, and C6 stereocenters of the kweichowenol-type natural products correspond to the C5, C6, and C7 stereocenters on the cyclohexane core of tetradotoxin. As such, we have laid the foundation towards an asymmetric synthesis of this celebrated target.^{17,18,24}

Acknowledgment

The authors thank Dr. Peter Mayer for X-Ray analyses. D.B.K is grateful to the Friedrich-Ebert-Stiftung for a PhD scholarship.

Supporting Information

Supporting information for this article is available online at <https://doi.org/10.1055/s-0037-1610390>.

References and Notes

- (1) Leboeuf, M.; Cavé, A.; Bhaumik, P. K.; Mukherjee, B.; Mukherjee, R. *Phytochemistry* **1980**, *21*, 2783.
- (2) Zhou, J.; Xie, G.; Yan, X. In *Encyclopedia of Traditional Chinese Medicines*, Vol. 3; Springer: Berlin, Heidelberg, **2011**.
- (3) Xu, J.-P. In *Cancer Inhibitors from Chinese Natural Medicines*; CRC Press: Boca Raton, FL, **2016**.
- (4) Nkunya, H. H. M.; Weenen, H.; Koyi, J. N.; Thijs, L.; Zwanenburg, B. *Phytochemistry* **1987**, *26*, 2563.
- (5) Jolad, S. D.; Hoffmann, J. J.; Schram, K. H.; Cole, J. R.; Tempesta, M. S.; Bates, R. B. *J. Org. Chem.* **1981**, *46*, 4267.
- (6) Schulte, G. R.; Ganem, B.; Chantrapromma, K.; Kodpinid, M.; Kobkull, S. *Tetrahedron Lett.* **1982**, *23*, 289.
- (7) Xu, Q.-M.; Liu, Y.-L.; Zou, Z.-M.; Yang, S.-L.; Xu, L.-Z. *J. Asian Nat. Prod. Res.* **2009**, *11*, 24.
- (8) Xu, Q.-M.; Zou, Z.-M.; Xu, L.-Z.; Yang, S.-L. *Chem. Pharm. Bull.* **2005**, *53*, 826.
- (9) Kijjoa, A.; Bessa, J.; Pinto, M. M. M.; Anatachoke, C.; Silva, A. M. S.; Eaton, G.; Herz, W. *Phytochemistry* **2002**, *59*, 543.
- (10) Fang, Y.; Ni, Z.-Y. N.; Yamada, T.; Wang, Y.-F.; Zhang, M.-L.; Dong, M.; Cong, B.; Sauriol, F.; Huo, C.-H.; Shi, Q.-W.; Kiyota, H. *Z. Naturforsch., B: J. Chem. Sci.* **2010**, *65*, 1401.
- (11) Yu, J. S.; Moon, E.; Choi, S. U.; Kim, K. H. *Tetrahedron Lett.* **2016**, *57*, 1699.
- (12) Bohman, B.; Tröger, A.; Franke, S.; Lorenzo, M. G. Francke W.; Unelius, C. R. *J. Nat. Prod.* **2011**, *74*, 690.
- (13) Kim, S. M.; Son, S.; Kim, J. W.; Jeon, E. S.; Ko, S.-K.; Ryoo, I.-J.; Shin, K.-S.; Hirota, H.; Takahashi, S.; Osada, H.; Jang, J.-H.; Ahn, J. S. *Nat. Prod. Sci.* **2015**, *21*, 231.
- (14) Rodrigues-Heerklotz, K. F.; Drandarov, K.; Heerklotz, J.; Hesse, M.; Werner, C. *Helv. Chim. Acta* **2001**, *84*, 3766.
- (15) Wirasathien, L.; Pengsuparp, T.; Moriyasu, M.; Kawanishi, K.; Suttisri, R. *Arch. Pharm. Res.* **2006**, *29*, 497.
- (16) Sun, Z.-L.; He, J.-M.; Wang, S.-Y.; Ma, R.; Khondkar, P.; Kaatz, G. W.; Gibbons, S.; Mu, Q. *RSC Adv.* **2016**, *6*, 43518.
- (17) Bane, V.; Lehane, M.; Dikshit, M.; Riordan, A.; Furey, A. *Toxins* **2014**, *6*, 693.
- (18) Goto, T.; Kishi, Y.; Takahashi, S.; Hirata, Y. *Tetrahedron* **1965**, *21*, 2059.
- (19) Tsubuki, M.; Okita, H.; Honda, T. *Heterocycles* **2006**, *67*, 731.
- (20) Bülow, L.; Naini, A.; Fohrer, J.; Kalesse, M. *Org. Lett.* **2011**, *13*, 6038.
- (21) Kiyooka, S.; Kaneko, Y.; Komura, M.; Matsuo, H.; Nakano, M. *J. Org. Chem.* **1991**, *56*, 2276.
- (22) **Kiyooka Aldol Reaction Procedure for the Synthesis of 12**
N-Ts-D-valine (**SI-1**, 7.82 g, 28.6 mmol, 1.1 equiv) was dissolved in CH₂Cl₂ (130 mL), cooled to 0 °C, and BH₃·THF (1 M in THF, 26.0 mL, 26.0 mmol, 1.0 equiv) was added dropwise over a period of 10 min. The suspension was stirred at 0 °C for 30 min before warming to rt and stirring for 1 h. Continuous bubbling was observed, and the white solid slowly dissolved to give a clear solution. After cooling the solution to -78 °C, cinnamaldehyde (**11**, 3.27 mL, 26.0 mmol, 1.0 equiv) in CH₂Cl₂ (70 mL) and TBS ketene acetal (**9**, 8.56 mL, 31.2 mmol, 1.2 equiv) in CH₂Cl₂ (70 mL) were successively added via syringe pump (2.5 mL/min). Stirring was continued for 10 min at -78 °C and PB pH

7 (30 mL) was added at -78°C . The mixture was diluted with Et_2O (500 mL), and the organic layer was washed with PB pH 7/sat. aq. NaCl (4:1, 250 mL), sat. aq. NaHCO_3 (200 mL), and sat. aq. NaCl (200 mL) before drying over Na_2SO_4 . Concentrating the organic phase under reduced pressure provided an oily residue which was directly dissolved in $\text{EtOH}/\text{H}_2\text{O}$ (9:1, 57.2 mL). After addition of NaHSO_3 (2.70 g, 26.0 mmol, 1.0 equiv), the suspension was heated to 37°C for 3 h followed by filtration through Celite and rinsing of the filter cake with Et_2O . The filtrate was concentrated *in vacuo*, redissolved in Et_2O (100 mL) and filtered again through Celite. Rotary evaporation gave an oily residue that was purified via flash column chromatography (pentane/ Et_2O = 185:15) to give an intractable diastomeric mixture of (1*S,E*)-[[*(4R)*-4-[[*(tert*-butyldimethylsilyloxy)(methoxy)methyl]-2,2-dimethyl-1,3-dioxolan-4-yl]-3-phenylprop-2-en-1-ol (**12**, 7.08 g, 17.3 mmol, 67%) as a clear oil.

Analytical Data of **12-1**

R_f (pentane/ Et_2O = 9:1) = 0.24. (UV, CAM). ^1H NMR (400 MHz, CD_2Cl_2): δ = 7.42–7.38 (m, 2 H), 7.34–7.28 (m, 2 H), 7.25–7.19 (m, 1 H), 6.65 (dd, J = 16.0, 1.6 Hz, 1 H), 6.41 (dd, J = 16.0, 5.4 Hz, 1 H), 4.80 (s, 1 H), 4.46 (td, J = 6.0, 1.7 Hz, 1 H), 4.00 (q, J = 9.3 Hz, 2 H), 3.44 (s, 3 H), 3.14 (d, J = 6.1 Hz, 1 H), 1.43 (s, 6 H), 0.92 (s, 9 H), 0.17 (s, 3 H), 0.17 (s, 3 H) ppm. ^{13}C NMR (101 MHz, CD_2Cl_2): δ = 137.8, 130.8, 129.3, 129.0, 127.8, 126.9, 111.3, 102.0, 86.4, 73.7, 67.8, 57.7, 27.1, 26.7, 26.1, 18.5, -4.1 , -4.2 ppm. HRMS (EI): m/z calcd for $\text{C}_{21}\text{H}_{33}\text{O}_5\text{Si}^+$ [$\text{M} - \text{CH}_3$] $^+$: 393.2097; found: 393.2095. IR (Diamond-ATR, neat): ν_{max} = 3504 (vw), 2955, 2931, 2897 (vw), 2858 (vw), 1741 (vw), 1496 (vw), 1472, 1463, 1449 (vw), 1380, 1370, 1252, 1210, 1063 (vs), 1005, 968, 939, 834 (vs), 778, 750, 693, 670 cm^{-1} . $[\alpha]_{\text{D}}^{20}$ -8.00 (c = 1.99, EtOAc).

(23) Selective Benzoylation Procedure for the Synthesis of Kweichowenol A (**1**)

Diol (**17**, 4.7 mg, 15 μmol , 1.0 equiv) was dissolved in pyridine (0.15 mL), cooled to -27°C , and BzCl (1.78 μL , 15.4 μL , 1.05 equiv) in pyridine (0.1 mL) was added dropwise. The solution was allowed to warm to -20°C over a period of 15 min and stirring was continued at the same temperature for 40 min. Thereafter, 3% aq. KHSO_4 (1 mL) was added, and the mixture was diluted with EtOAc (30 mL). The organic layer was washed with 3% aq. KHSO_4 (10 mL), sat. aq. NaCl (10 mL), dried over Na_2SO_4 , and concentrated. Purification via flash column chromatography (pentane/ EtOAc = 9:1 \rightarrow 8:1) afforded kweichowenol A (**1**, 4.3 mg, 10 μmol , 69%) as a white solid.

Analytical Data of Synthetic Kweichowenol A (1**)** R_f (pentane/ EtOAc = 19:1) = 0.21. (UV, CAM). ^1H NMR (600 MHz, C_6D_6): δ = 8.17–8.14 (m, 2 H), 8.10–8.08 (m, 2 H), 7.62–7.56 (m, 2 H), 7.50–7.44 (m, 4 H), 5.85–5.79 (m, 2 H), 5.79–5.78 (m, 1 H), 5.61 (ddd, J = 8.6, 2.5, 1.4 Hz, 1 H), 4.38 (d, J = 8.4 Hz, 1 H), 4.33 (d, J = 8.4 Hz, 1 H), 4.28 (d, J = 8.5 Hz, 1 H), 2.64 (s, 1 H), 1.46 (s, 3 H), 1.32 (s, 3 H) ppm. ^{13}C NMR (151 MHz, C_6D_6): δ = 166.5, 166.0, 133.6, 133.5, 130.2, 130.0, 129.77, 129.76, 129.4, 128.7, 128.6, 127.5, 111.1, 85.6, 74.2, 73.8, 72.4, 64.5, 27.0, 26.2 ppm. HRMS (ESI): m/z calcd for $\text{C}_{26}\text{H}_{27}\text{O}_9^-$ [$\text{M} + \text{CH}_3\text{COO}^-$] $^-$: 483.1661; found: 483.1665. IR (Diamond-ATR, neat): ν_{max} = 3588 (vw), 2920, 2851 (vw), 2166, 1714, 1600 (vw), 1453, 1382 (vw), 1369, 1316, 1268 (vs), 1206, 1177, 1147 1111, 1089, 1064 (vs), 1023, 962, 881, 863, 798, 780, 701 (vs), 668 cm^{-1} . $[\alpha]_{\text{D}}^{20}$ -168° (c = 0.538, CHCl_3).

(24) Nicolaou, K. C.; Chen, J. S. In *Classics in Total Synthesis III.*; Wiley-VCH: Weinheim, 2011.